Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Krauth, MT; Burgstaller, S; Buxhofer-Ausch, V; Gastl, G; Geissler, K; Keil, F; Krippl, P; Melchardt, T; Petzer, A; Rumpold, H; Sliwa, T; Wohrer, S; Wolfler, A; Gisslinger, H.
Ruxolitinib therapy for myelofibrosis in Austria Consensus on therapy management
WIEN KLIN WOCHENSCHR. 2018; 130(17-18): 495-504. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Autor/innen der Med Uni Graz:
Krippl Peter
Wölfler Albert

Dimensions Citations:

Plum Analytics:
The oral Janus associated kinase (JAK1/2) inhibitor ruxolitinib has been available for treatment of patients with intermediate or high-risk myelofibrosis in Europe since 2012. Since its introduction, the expertise of prescribing doctors with respect to ruxolitinib function, efficacy and adverse effects has consistently been augmented, resulting in therapy modalities that are better tailored to individual patients as well as in increased safety of the treatment. The present consensus on ruxolitinib therapy management has been elaborated by Austrian experts in myeloproliferative neoplasms in line with international treatment guidelines. Our recommendations aim to contribute to an improved management of patients with myelofibrosis treated with ruxolitinib.

Find related publications in this database (Keywords)
Janus kinase 2
Myeloproliferative disorders
Primary myelofibrosis
Post-polycythemia vera myelofibrosis
Post-essential thrombocythemia myelofibrosis
© Meduni Graz Impressum